DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Antithyroid Drugs Tied to Risk for Congenital Malformations
Infants born to women who received antithyroid drugs (ATDs) for Graves disease (GD) during the first trimester of pregnancy have an increased risk for congenital malformations, a study has found.
“ATD exposure during the first trimester was associated with significantly increased risk for congenital malformations, particularly for pregnancies in which women received prescriptions for MMI [methimazole] or both ATDs” (MMI or propylthiouracil [PTU]), the researchers write.
Gi Hyeon Seo, MD, from Health Insurance Review and Assessment Service, Wonju-si, Gangwon-do, Korea, and colleagues published their findings online today in Annals of Internal Medicine.
The authors note, however, that the risk to the fetus must be balanced against the mothers’ risks. “Untreated or insufficiently treated GD may result in pregnancy loss and serious fetal and maternal sequelae, providing a compelling indication for timely administration of antithyroid drugs,” the researchers explain.


Related Content
-
Evidence & EducationDouble-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves HyperthyroidismContext: Supplemental selenium (Se) may...
-
Evidence & EducationDrug Effects on the ThyroidThe list of medications, many commonly u...
-
Evidence & EducationGraves’ Disease and Pregnancy PlanningBoth hypothyroidism and hyperthyroidism ...
-
Videos & VisualsUnderstanding Autoimmune Thyroid Diseasehttps://www.youtube.com/watch?v=Gl1-INPQ...
-
Evidence & EducationA Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Grav...Context: Radioiodine is an effective an...
-
People & PlacesDouglas S. Ross, MDDouglas S. Ross is a Co-director of Thyr...
-
Evidence & Education2018 European Thyroid Association Guideline for the Management of Graves’ HyperthyroidismGraves' disease (GD) is a systemic autoi...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.